The uncontrolled study offers support for intrathecal administration of autologous mesenchymal stem cells that secrete neurotrophic factors. Investigators call for randomized studies to better explore effects on symptoms and disease activity.
Serum Neurofilament Light as a Progressive MS Biomarker: Guideposts for the Road Ahead
This protein shows promise as a biomarker for use in early-stage therapeutic trials, but more work is needed. An expert panel has outlined what should be done next to rapidly realize its potential.
Therapeutics for Progressive Multiple Sclerosis: Where to Go from Here?
A leading MS researcher shares three potential explanations for why the well-designed MS-SMART investigation didn’t identify any therapies to carry forward into phase 3 trials.
SPRINT-MS: Ibudilast Shows Unprecedented Slowing of Brain Atrophy in Progressive MS
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy